Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Receivables - Net (2016 - 2023)

Historic Receivables - Net for Avalo Therapeutics (AVTX) over the last 8 years, with Q2 2023 value amounting to $38000.0.

  • Avalo Therapeutics' Receivables - Net fell 9301.47% to $38000.0 in Q2 2023 from the same period last year, while for Jun 2023 it was $38000.0, marking a year-over-year decrease of 9301.47%. This contributed to the annual value of $1.1 million for FY2021, which is 5130.91% down from last year.
  • Latest data reveals that Avalo Therapeutics reported Receivables - Net of $38000.0 as of Q2 2023, which was down 9301.47% from $544000.0 recorded in Q2 2022.
  • Over the past 5 years, Avalo Therapeutics' Receivables - Net peaked at $5.0 million during Q3 2019, and registered a low of $38000.0 during Q2 2023.
  • Over the past 5 years, Avalo Therapeutics' median Receivables - Net value was $2.0 million (recorded in 2020), while the average stood at $2.1 million.
  • In the last 5 years, Avalo Therapeutics' Receivables - Net surged by 11734.25% in 2020 and then plummeted by 9301.47% in 2023.
  • Over the past 5 years, Avalo Therapeutics' Receivables - Net (Quarter) stood at $1.0 million in 2019, then skyrocketed by 117.34% to $2.2 million in 2020, then plummeted by 51.31% to $1.1 million in 2021, then plummeted by 48.68% to $544000.0 in 2022, then tumbled by 93.01% to $38000.0 in 2023.
  • Its Receivables - Net stands at $38000.0 for Q2 2023, versus $544000.0 for Q2 2022 and $938000.0 for Q1 2022.